Innate immunity cell activation in virologically suppressed HIV-infected maraviroc-treated patients

AIDS

Volumn 28, Issue 7, 2014, Pages 1071-1074

  Dentone, Chiara ^a,b   Di Biagio, Antonio ^c   Parodi, Alessia ^b   Bozzano, Federica ^b,d   Fraccaro, Paolo ^e   Signori, Alessio ^b   Cenderello, Giovanni ^f   Mantia, Eugenio ^g   Orofino, Giancarlo ^h   De Maria, Andrea ^b,c,i   Filaci, Gilberto ^b   Fenoglio, Daniela ^b  

^a Sanremo Hospital   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d DIMES Department of Experimental Medicine   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f GALLIERA HOSPITAL   (Italy)

^g SS Antonio e Biagio   (Italy)

^h AMEDEO DI SAVOIA HOSPITAL   (Italy)

ⁱ Infectious Diseases Department Amedeo di Savoia Hospital ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD11B ANTIGEN; CD16 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHOLESTEROL; D DIMER; MARAVIROC; TRIACYLGLYCEROL; ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; CYCLOHEXANE DERIVATIVE; HLA ANTIGEN; LEUKOCYTE ANTIGEN; TRIAZOLE DERIVATIVE;

ADULT; AGE; ANTIVIRAL THERAPY; ARTERIAL PRESSURE; ARTICLE; BODY MASS; CASE CONTROL STUDY; CELL ACTIVATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOCYTE; NATURAL KILLER CELL; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; CHEMISTRY; HIV INFECTIONS; IMMUNOLOGY; TREATMENT OUTCOME;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIGENS, CD; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; CYCLOHEXANES; FEMALE; HIV INFECTIONS; HLA ANTIGENS; HUMANS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MONOCYTES; TREATMENT OUTCOME; TRIAZOLES;

EID: 84897490401     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000194     Document Type: Article

References (48)

1. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virusspecific CD8Rcytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68:6103-6110.
2. Levy JA. The importance of the innate immune system in controlling HIV infection and disease. Trends Immunol 2001; 22:312-316.
3. Fogli M, Costa P, Murdaca G, Setti M, Mingari MC, Moretta L, et al. Significant NK cell activation associated with decreased cytolytic function in peripheral blood of HIV-1-infected patients. Eur J Immunol 2004; 34:2313-2321.
4. Naranbhai V, Altfeld M, Karim SS, Ndung'u T, Karim QA, Carr WH. Changes in natural killer cell activation and function during primary HIV-1 infection. PLoS One 2013; 8:e53251.
5. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, et al. T cell activation is associated with lower CD4R T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-1543.
6. Costa P, Rusconi S, Mavilio D, Fogli M, Murdaca G, Pende D, et al. Differential disappearance of inhibitory natural killer cell receptors during HAART and possible impairment of HIV-1-specific CD8 cytotoxic T lymphocytes. AIDS 2001; 15:965-974.
7. Lichtfuss GF, Cheng WJ, Farsakoglu Y, Paukovics G, Rajasuriar R, Velayudham P, et al. Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation. J Immunol 2012; 189:1491-1499.
8. Bisio F, Bozzano F, Marras F, Di Biagio A, Moretta L, De Maria A. Successfully treated HIV-infected patients have differential expression of NK cell receptors (NKp46 and NKp30) according to AIDS status at presentation. Immunol Lett 2013; 152:16-24.
9. Hearps AC, Maisa A, Cheng WJ, Angelovich TA, Lichtfuss GF, Palmer CS, et al. HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. AIDS 2012; 26:843-853.
10. Martin GE, Gouillou M, Hearps AC, Angelovich TA, Cheng AC, Lynch F, et al. Age-associated changes in monocyte and innate immune activation markers occur more rapidly in HIV infected women. PLoS One 2013; 8:e55279.
11. Funderburg N, Kalinowska M, Eason J, Goodrich J, Heera J, Mayer H, et al. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4R cell rises in HIV-infected patients. PloS One 2010; 5:e13188.
12. Rossi R, Lichtner M, De Rosa A, Sauzullo I, Mengoni F, Massetti AP, et al. In vitro effect of antihuman immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells. Clin Exp Immunol 2011; 166:184-190.
13. Cipriani S, Francisci D, Mencarelli A, Renga B, Schiaroli E, D'Amore C, et al. Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. Circulation 2013; 127:2114-2124.
14. Crowe SM, Westhorpe CL, Mukhamedova N, Jaworowski A, Sviridov D, Bukrinsky M. The macrophage: the intersection between HIV infection and atherosclerosis. J Leukoc Biol 2010; 87:589-598.
15. Fraccaro P, Dentone C, Fenoglio D, Giacomini M. Multicentre clinical trials' data management: a hybrid solution to exploit the strengths of electronic data capture and electronic health records systems. Inform Health Soc Care 2013; 38:313-329.
16. Fraccaro P, Pupella V, Gazzarata R, Dentone C, Cenderello G, De Leo P, et al. The Ligurian Human Immunodeficiency Virus Clinical Network: a web tool to manage patients with human immunodeficiency virus in primary care and multicenter clinical trials. Medicine 20 2013; 2:e5doi:10.2196/med20.2712.
17. Chuang-Stein C. Summarizing laboratory data with different reference ranges in multi-center clinical trials. Drug Inform J 1992; 26:77-84.
18. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010; 116:e74-e80.
19. Musso T, Deaglio S, Franco L, Calosso L, Badolato R, Garbarino G, et al. CD38 expression and functional activities are upregulated by IFN-gamma on human monocytes and monocytic cell lines. J Leukoc Biol 2001; 69:605-612.
20. Cheng X, Veverka V, Radhakrishnan A, Waters LC, Muskett FW, Morgan SH, et al. Structure and interactions of the human programmed cell death 1 receptor. J Biol Chem 2013; 288:11771-11785.
21. Weber C, Belge KU, von Hundelshausen P, Draude G, Steppich B, Mack M, et al. Differential chemokine receptor expression and function in human monocyte subpopulations. J Leukoc Biol 2000; 67:699-704.
22. Dosquet C, Weill D, Wautier JL. Molecular mechanism of blood monocyte adhesion to vascular endothelial cells. Nouv Rev Fr Hematol 1992; 34 (Suppl):S55-S59.
23. Burdo TH, Lentz MR, Autissier P, Krishnan A, Halpern E, Letendre S, et al. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after antiretroviral therapy. J Infect Dis 2011; 204:154-163.
24. Calder PC, Ahluwalia N, Brouns F, Buetler T, Clement K, Cunningham K, et al. Dietary factors and low-grade inflammation in relation to overweight and obesity. Br J Nutr 2011; 106 (Suppl 3):S5-S78.
25. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virusspecific CD8Rcytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68:6103-6110.
26. Levy JA. The importance of the innate immune system in controlling HIV infection and disease. Trends Immunol 2001; 22:312-316.
27. Fogli M, Costa P, Murdaca G, Setti M, Mingari MC, Moretta L, et al. Significant NK cell activation associated with decreased cytolytic function in peripheral blood of HIV-1-infected patients. Eur J Immunol 2004; 34:2313-2321.
28. Naranbhai V, Altfeld M, Karim SS, Ndung'u T, Karim QA, Carr WH. Changes in natural killer cell activation and function during primary HIV-1 infection. PLoS One 2013; 8:e53251.
29. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, et al. T cell activation is associated with lower CD4R T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-1543.
30. Costa P, Rusconi S, Mavilio D, Fogli M, Murdaca G, Pende D, et al. Differential disappearance of inhibitory natural killer cell receptors during HAART and possible impairment of HIV-1-specific CD8 cytotoxic T lymphocytes. AIDS 2001; 15:965-974.
31. Lichtfuss GF, Cheng WJ, Farsakoglu Y, Paukovics G, Rajasuriar R, Velayudham P, et al. Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation. J Immunol 2012; 189:1491-1499.
32. Bisio F, Bozzano F, Marras F, Di Biagio A, Moretta L, De Maria A. Successfully treated HIV-infected patients have differential expression of NK cell receptors (NKp46 and NKp30) according to AIDS status at presentation. Immunol Lett 2013; 152:16-24.
33. Hearps AC, Maisa A, Cheng WJ, Angelovich TA, Lichtfuss GF, Palmer CS, et al. HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. AIDS 2012; 26:843-853.
34. Martin GE, Gouillou M, Hearps AC, Angelovich TA, Cheng AC, Lynch F, et al. Age-associated changes in monocyte and innate immune activation markers occur more rapidly in HIV infected women. PLoS One 2013; 8:e55279.
35. Funderburg N, Kalinowska M, Eason J, Goodrich J, Heera J, Mayer H, et al. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4R cell rises in HIV-infected patients. PloS One 2010; 5:e13188.
36. Rossi R, Lichtner M, De Rosa A, Sauzullo I, Mengoni F, Massetti AP, et al. In vitro effect of antihuman immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells. Clin Exp Immunol 2011; 166:184-190.
37. Cipriani S, Francisci D, Mencarelli A, Renga B, Schiaroli E, D'Amore C, et al. Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. Circulation 2013; 127:2114-2124.
38. Crowe SM, Westhorpe CL, Mukhamedova N, Jaworowski A, Sviridov D, Bukrinsky M. The macrophage: the intersection between HIV infection and atherosclerosis. J Leukoc Biol 2010; 87:589-598.
39. Fraccaro P, Dentone C, Fenoglio D, Giacomini M. Multicentre clinical trials' data management: a hybrid solution to exploit the strengths of electronic data capture and electronic health records systems. Inform Health Soc Care 2013; 38:313-329.
40. Fraccaro P, Pupella V, Gazzarata R, Dentone C, Cenderello G, De Leo P, et al. The Ligurian Human Immunodeficiency Virus Clinical Network: a web tool to manage patients with human immunodeficiency virus in primary care and multicenter clinical trials. Medicine 20 2013; 2:e5doi:10.2196/med20.2712.
41. Chuang-Stein C. Summarizing laboratory data with different reference ranges in multi-center clinical trials. Drug Inform J 1992; 26:77-84.
42. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010; 116:e74-e80.
43. Musso T, Deaglio S, Franco L, Calosso L, Badolato R, Garbarino G, et al. CD38 expression and functional activities are upregulated by IFN-gamma on human monocytes and monocytic cell lines. J Leukoc Biol 2001; 69:605-612.
44. Cheng X, Veverka V, Radhakrishnan A, Waters LC, Muskett FW, Morgan SH, et al. Structure and interactions of the human programmed cell death 1 receptor. J Biol Chem 2013; 288:11771-11785.
45. Weber C, Belge KU, von Hundelshausen P, Draude G, Steppich B, Mack M, et al. Differential chemokine receptor expression and function in human monocyte subpopulations. J Leukoc Biol 2000; 67:699-704.
46. Dosquet C, Weill D, Wautier JL. Molecular mechanism of blood monocyte adhesion to vascular endothelial cells. Nouv Rev Fr Hematol 1992; 34 (Suppl):S55-S59.
47. Burdo TH, Lentz MR, Autissier P, Krishnan A, Halpern E, Letendre S, et al. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after antiretroviral therapy. J Infect Dis 2011; 204:154-163.
48. Calder PC, Ahluwalia N, Brouns F, Buetler T, Clement K, Cunningham K, et al. Dietary factors and low-grade inflammation in relation to overweight and obesity. Br J Nutr 2011; 106 (Suppl 3):S5-S78.